This review presents relevant background information on chronic spontaneous urticaria (CSU) and focuses on pharmacologic management strategies. In particular, it highlights research providing support for the use of omalizumab in patients with CSU who remain symptomatic despite H1 antihistamine treatment.
Independent commentary has been provided by Dr Connie Katelaris, a Professor of Immunology & Allergy at the University of Western Sydney and Head of Department and Senior Staff Specialist at Campbelltown Hospital.
Please login below to download this issue (PDF)